Clinical Trials Logo
  1. Home
  2. Intestinal Diseases
  3. NCT01192802
  4. Details
NCT01192802 Clinical Trial

Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora

Intestinal Diseases Clinical Trial

Official title:
Effect of Intestinal Helminths on Gut Microflora

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01192802
Other study ID # Albendazole-001
Secondary ID
Status Completed
Phase Phase 4
First received August 31, 2010
Last updated January 23, 2013
Start date August 2010
Est. completion date July 2012

Study information
Verified date January 2013
Source Albert Schweitzer Hospital
Contact n/a
Is FDA regulated No
Health authority Lambarene: Albert Schweitzer Hospital
Study type Interventional

Clinical Trial Summary

Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy in the school children population. The aim of this study is to evaluate the efficacy of the albendazole one versus two and three doses, in school children infected with intestinal helminth.

Recruitment information / eligibility
Status Completed
Enrollment 200
Est. completion date July 2012
Est. primary completion date July 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 4 Years to 14 Years
Eligibility Inclusion Criteria:

- presence of intestinal helminths eggs in the stool

Exclusion Criteria:

- allergy to imidazole derivate

- No intestinal helminths

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• albendazole
1 tablet of 400 mg of albendazole per day for three consecutive days
• albendazole
single 1 tablet of 400 mg of albendazole
• albendazole
1 tablet of 400 mg of albendazole per day for two consecutive days

Locations
Country Name City State
Gabon Medical research Unit of Lambaréné Lambarene Moyen ogooue

Sponsors (1)
Lead Sponsor Collaborator
Albert Schweitzer Hospital

Country where clinical trial is conducted

Gabon, 

Outcome
Type Measure Description Time frame Safety issue
Primary parasite cleared and reduced up to 80% at day 42 42 days No
Secondary Prevalence of major gut bacteria Change in the prevalence of major gut bacteria after antihelminth treatment. 42 days No
See also
  Status Clinical Trial Phase
Completed NCT03032861 - The Prebiotic Effect of Daily Intake of Orange Juice Affects the Bioavailability of Flavanones? N/A
Recruiting NCT02295254 - Microbiome Changes in Travelers to Tropical Destinations N/A
Completed NCT02246647 - Biomarkers for Intestinal Permeability in Patients With Constipation
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Active, not recruiting NCT01037049 - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Phase 2
Completed NCT01872286 - Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2 N/A
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02445365 - Remote Ischemic Conditioning in Patients With Ulcerative Colitis N/A
Recruiting NCT04949282 - Spanish Series of Patients Treated With the Radionuclide Lutetium177
Active, not recruiting NCT01995942 - Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Completed NCT02693782 - Fabulous Fibre Study - Effect of Wheat Bran Extract on Gut and General Health in Healthy Aging Subjects (FFS) N/A
Not yet recruiting NCT02806206 - Prucalopride Prior to Small Bowel Capsule Endoscopy Phase 4
Completed NCT02831556 - Point of Care 3D Ultrasound for Various Applications: A Pilot Study
Terminated NCT04102163 - Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment
Terminated NCT02550860 - Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function Phase 3
Recruiting NCT02044952 - Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission Phase 2/Phase 3
Completed NCT02227602 - Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease N/A
Active, not recruiting NCT01028898 - Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome N/A

External Links